PLT Expanding MenaQ7 Indications

MORRISTOWN, N.J.—P.L. Thomas & Co. (PLT) announced new patent-pending indications for its natural natto-sourced vitamin K2, MenaQ7™. An alliance between PLT, Natto Pharma and VitaK BV allows MenaQ7 to be offered for cardiovascular health benefits, with proprietary research and U.S. patents pending. PLT is the exclusive North American representative for Natto Pharma, the supplier of MenaQ7, which acquired three pending U.S. patents from VitaK in the areas of cardiovascular disease/mortality and regression of arterial calcification.

“We are delighted to present to our clients what we firmly believe is the most viable vitamin K2 opportunity in all respects,” said Paul Flowerman, PLT president. “MenaQ7 directly addresses important bone and cardiovascular wellness issues. It is manufactured under GMP [good manufacturing practice] conditions, reliably supplied, and is supported by a total commitment to the best existing and ongoing research and intellectual property development.”

For more information, visit www.plthomas.com or Booth #6077 at SupplySide West.